William Blair & Co. added 20% to its holdings in NxStage Medical (NSDQ:NXTM) last year, according to regulatory filings.
The Chicago-based investment bank owned more than 3.8 million NXTM shares as of Dec. 31, 2012, up 19.5% from the 3.2 million shares it owned at the close of 2011.
That amounts to a 6.5% stake in Lawrence, Mass.-based NxStage, which makes home hemodialysis equipment.
Sign up to get our free newsletters delivered straight to your inbox
Covidien’s Mallinckrodt pharma spinout will list on NYSE
Covidien (NYSE:COV) said the spinout of its pharmaceuticals business, Mallinckrodt, will list on the New York Stock Exchange under the MNK symbol. The spinout is expected to take effect some time in the middle of 2013.
Read more
Neusoft to buy out Philips’ share in JV
Neusoft (SHA:600718) said it plans to buy out the 51% stake owned by Philips (NYSE:PHG) in their joint venture, Philips Neusoft Medical Systems.
Read more
Echo Therapeutics offering tops $10M
Echo Therapeutics (NSDQ:ECTE) grossed $10.2 million from a public offering of more than 13.6 million shares of its common stock at 75¢ apiece.
The Philadelphia-based medical device company plans to use some of the cash to pay down debt and for "general corporate purposes."
Read more
Heart valve maker Micardia raises $3M
Heart valve maker Micardia raised $3.0 million of a hoped-for $5 million round from 17 unnamed investors.
Read more
Analysts’ ups and downs
- Cyberonics (NSDQ:CYBX): Piper Jaffray reiterates "overweight" rating, $55 price target.
- Edwards Lifesciences (NYSE:EW): Canaccord Genuity reiterates "buy" rating, raises price target from $109 to $115; Leerink Swann reiterates "outperform" rating, $100 price target.
- Hologic (NSDQ:HOLX): Leerink Swann increases price target to $28 from $25, maintains "outperform" rating.
- St. Jude Medical (NYSE:STJ): Mizuho Securities raises price target to $48 from $46.
